51.91
-1.41 (-2.64%)
| Previous Close | 53.32 |
| Open | 53.05 |
| Volume | 1,748,730 |
| Avg. Volume (3M) | 2,932,755 |
| Market Cap | 9,792,198,656 |
| Price / Earnings (Forward) | 2.50 |
| Price / Sales | 2.98 |
| Price / Book | 3.60 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 |
| Profit Margin | -36.06% |
| Operating Margin (TTM) | -11.53% |
| Diluted EPS (TTM) | -5.53 |
| Quarterly Revenue Growth (YOY) | 10.90% |
| Total Debt/Equity (MRQ) | 105.93% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | 323.66 M |
| Levered Free Cash Flow (TTM) | 163.08 M |
| Return on Assets (TTM) | -1.83% |
| Return on Equity (TTM) | -36.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Exact Sciences Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 98.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 64.00 (Evercore ISI Group, 23.29%) | Buy |
| Median | 57.50 (10.77%) | |
| Low | 46.00 (RBC Capital, -11.39%) | Hold |
| Average | 56.33 (8.52%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 42.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 12 Aug 2025 | 60.00 (15.58%) | Buy | 41.74 |
| Piper Sandler | 11 Aug 2025 | 60.00 (15.58%) | Buy | 40.91 |
| Evercore ISI Group | 08 Aug 2025 | 64.00 (23.29%) | Buy | 40.99 |
| 08 Jul 2025 | 68.00 (31.00%) | Buy | 53.54 | |
| Barclays | 07 Aug 2025 | 55.00 (5.95%) | Buy | 43.16 |
| 24 Jun 2025 | 65.00 (25.22%) | Buy | 51.17 | |
| RBC Capital | 07 Aug 2025 | 46.00 (-11.39%) | Hold | 43.16 |
| UBS | 07 Aug 2025 | 53.00 (2.10%) | Hold | 43.16 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Aug 2025 | Announcement | Exact Sciences to Participate in September Investor Conferences |
| 31 Jul 2025 | Announcement | Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test |
| 14 Jul 2025 | Announcement | Exact Sciences Schedules Second Quarter 2025 Earnings Call |
| 09 Jul 2025 | Announcement | Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |